drugset / Trial / NCT03487588

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

NCT03487588

Phase 4 Completed 41 enrolled Aclaris Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.

Timeline

Start
2018-03-21
Primary completion
2018-11-14
Completion
2018-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 40 % Topical

Indications